Results 1 to 10 of about 14,668 (165)
Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials [PDF]
Although daratumumab has been reported to significantly improve the prognosis of multiple myeloma (MM), its efficacy in patients with cytogenetically high-risk MM (HRMM) remains unclear.
Liang Su +4 more
doaj +2 more sources
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies.
Djamila Chemlal +15 more
doaj +1 more source
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu +21 more
doaj +1 more source
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer +7 more
doaj +1 more source
Daratumumab in untreated newly diagnosed multiple myeloma
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Nadine Abdallah, Shaji K. Kumar
doaj +1 more source
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC.
Rathi N. Pillai, MD +12 more
doaj +1 more source
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or ...
Andrew Spencer +36 more
doaj +1 more source
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner +2 more
doaj +1 more source
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated with ...
Agoston Gyula Szabo +17 more
doaj +1 more source
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease.
Jennifer Yang +15 more
doaj +1 more source

